<table id="t2" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2:  Clinically Significant Drug Interactions with CONZIP
</caption>
<col align="left" width="21.500%"></col>
<col align="left" width="78.500%"></col>
<tbody>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Inhibitors of CYP2D6</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of CONZIP and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of CONZIP is achieved. Since M1 is a more potent Î¼-opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome.<br/>
<br/>After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease and the M1 plasma concentration will increase  which could increase or prolong therapeutic effects but also increase adverse reactions related to opioid toxicity, and may cause potentially fatal respiratory depression  <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s82">12.3</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use of a CYP2D6 inhibitor is necessary, follow patients closely for adverse reactions including opioid withdrawal, seizures, and serotonin syndrome.<br/>
<br/>If a CYP2D6 inhibitor is discontinued, consider lowering CONZIP dosage until stable drug effects are achieved. Follow patients closely for adverse events including respiratory depression and sedation.<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Quinidine, fluoxetine, paroxetine and bupropion
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Inhibitors of CYP3A4</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of CONZIP and CYP3A4 inhibitors can increase the plasma concentration of tramadol and may result in a greater amount of metabolism via CYP2D6 and greater levels of M1. Follow patients closely for increased risk of serious adverse events including seizures and serotonin syndrome, and adverse reactions related to opioid toxicity including potentially fatal respiratory depression,     particularly when an inhibitor is added after a stable dose of CONZIP is achieved.<br/>
<br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s82">12.3</linkhtml>)]</content>, resulting in decreased opioid efficacy and possibly signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is necessary, consider dosage reduction of CONZIP until stable drug effects are achieved. Follow patients closely for seizures and serotonin syndrome, and signs of respiratory depression and sedation at frequent intervals.<br/>If a CYP3A4 inhibitor is discontinued, consider increasing the CONZIP dosage until stable drug effects are achieved and follow patients for signs and symptoms of opioid withdrawal.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of CONZIP and CYP3A4 inducers can decrease the plasma concentration of tramadol, <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s82">12.3</linkhtml>)]</content>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to tramadol, <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s25">5.4</linkhtml>)]</content>.<br/>
<br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the tramadol plasma concentration will increase <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#s82">12.3</linkhtml>)]</content>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause seizures and serotonin syndrome, and potentially fatal respiratory depression .
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is necessary, consider increasing the CONZIP dosage until stable drug effects are achieved. Follow patients for signs of opioid withdrawal.<br/>If a CYP3A4 inducer is discontinued, consider CONZIP dosage reduction and monitor for seizures and serotonin syndrome, and signs of sedation and respiratory depression.<br/>
<br/>Patients taking carbamazepine, a CYP3A4 inducer, may have a significantly reduced analgesic effect of tramadol. Because carbamazepine increases tramadol metabolism and because of the seizure risk associated with tramadol, concomitant administration of CONZIP and carbamazepine is not recommended.<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Rifampin, carbamazepine, phenytoin
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s28">5.5</linkhtml>)]</content>.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, , antipsychotics, other opioids, alcohol.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Serotonergic Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.  Discontinue CONZIP if serotonin syndrome is suspected.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">MAOI interactions with opioids may manifest as serotonin syndrome <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s30">5.7</linkhtml>)]</content> or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#s23">5.2</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Do not use CONZIP in patients taking MAOIs or within 14 days of stopping such treatment.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">phenelzine, tranylcypromine, linezolid
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May reduce the analgesic effect of CONZIP and/or precipitate withdrawal symptoms.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Avoid concomitant use.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">butorphanol, nalbuphine, pentazocine, buprenorphine
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Tramadol may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of CONZIP and/or the muscle relaxant as necessary.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Anticholinergic Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of urinary retention or reduced gastric motility when CONZIP is used concomitantly with anticholinergic drugs.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Digoxin</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Post-marketing surveillance of tramadol has revealed rare reports of digoxin toxicity.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Follow patients for signs of digoxin toxicity and adjust dosage of digoxin as needed.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Warfarin</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Post-marketing surveillance of tramadol has revealed rare reports of alteration of warfarin effect, including elevation of prothrombin times.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor the prothrombin time of patients on warfarin for signs of an interaction and adjust the dosage of warfarin as needed.
</td>
</tr>
</tbody>
</table>